2 reports

It is used as an adjunct to cancer chemotherapy for its effect on preventing neutropenia and accelerating neutrophil recovery after chemotherapy.

  • Blood Disease
  • Cancer
  • Leukemia
  • Therapy
  • Ltd Sichuang Open Pharmaceutical Co., Ltd
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.